Back to Search Start Over

A multi-center, prospective, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients

Authors :
Wei Bai
Fan Yang
Huji Xu
Wei Wei
Hongbin Li
Liyun Zhang
Yi Zhao
Xiaofei Shi
Yan Zhang
Xiaofeng Zeng
Xiaomei Leng
Publication Year :
2022
Publisher :
Research Square Platform LLC, 2022.

Abstract

BackgroundPrimary Sjogren’s syndrome (pSS) is a systemic autoimmune disease involving multiple organ systems. The Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway is a key pathway involving the pathogenesis of pSS. Baricitinib, a selective JAK1 and JAK2 inhibitor, has been approved for treatment of active rheumatoid arthritis and reported in treatment of come other autoimmune diseases including systemic lupus erythematosus. We have found that baricitinib might be effective and safety in pSS in a pilot study. However, there is no published clinical evidence of baricitinib in pSS. Hence, we conducted this randomized study to further explore the efficacy and safety of baricitinib in pSS.MethodsThis is a multi-center, prospective, open-label, randomized study to compare the efficacy of baricitinib + hydroxychloroquine (HCQ) with HCQ alone in pSS patients. We plan to involve 87 active pSS patients with European League Against Rheumatism pSS disease activity index (ESSDAI) ≥ 5 from eight different tertiary centers in China. Patients will be randomized (2:1) to receive baricitinib 4mg per day + HCQ 400mg per day or HCQ 400mg per day alone. We will switch HCQ to baricitinib + HCQ if the patient in the latter group has no ESSDAI response at week 12. The final evaluation will be at week 24. The primary endpoint is the percentage of ESSDAI response, or minimal clinically important improvement (MCII), which was defined as an improvement of ESSDAI at least three points at week 12. The secondary endpoints include EULAR pSS patient reported index (ESSPRI) response, change of Physician's Global Assessment (PGA) score, serological activity parameters, salivary gland function test, and focus score on labial salivary gland biopsy.DiscussionThis is the first randomized controlled study to evaluate the clinical efficacy and safety of baricitinib in pSS. We hope that the result of this study can provide more reliable evidence of the efficacy and safety of baricitinib in pSS.Trial registrationClinicalTrials.gov, ID: NCT05016297. Registered 19 Aug 2021.

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........924db1ad89fab5afd5561135247e4fd9
Full Text :
https://doi.org/10.21203/rs.3.rs-1406859/v1